Waters Co. (WAT) Expected to Post Earnings of $2.11 Per Share

Equities analysts expect Waters Co. (NYSE:WAT) to report earnings per share (EPS) of $2.11 for the current quarter, according to Zacks. Six analysts have provided estimates for Waters’ earnings, with estimates ranging from $2.09 to $2.14. Waters posted earnings of $1.95 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 8.2%. The business is expected to report its next earnings report on Tuesday, July 23rd.

According to Zacks, analysts expect that Waters will report full-year earnings of $9.11 per share for the current financial year, with EPS estimates ranging from $9.07 to $9.17. For the next fiscal year, analysts expect that the business will report earnings of $10.26 per share, with EPS estimates ranging from $9.72 to $10.99. Zacks’ EPS calculations are an average based on a survey of research firms that follow Waters.

Waters (NYSE:WAT) last released its quarterly earnings data on Tuesday, April 23rd. The medical instruments supplier reported $1.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.73 by ($0.13). Waters had a return on equity of 39.64% and a net margin of 24.59%. The business had revenue of $513.90 million for the quarter, compared to analysts’ expectations of $545.82 million. During the same quarter in the prior year, the firm earned $1.59 earnings per share. Waters’s quarterly revenue was down 3.2% compared to the same quarter last year.



Several equities research analysts have issued reports on the stock. UBS Group decreased their price objective on shares of Waters from $248.00 to $230.00 and set a “neutral” rating for the company in a research note on Wednesday, April 24th. Zacks Investment Research downgraded shares of Waters from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 12th. Robert W. Baird decreased their price objective on shares of Waters from $211.00 to $209.00 and set a “neutral” rating for the company in a research note on Wednesday, April 24th. ValuEngine downgraded shares of Waters from a “buy” rating to a “hold” rating in a research note on Wednesday, April 24th. Finally, TheStreet upgraded shares of Waters from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $212.26.

WAT opened at $209.23 on Tuesday. The company has a quick ratio of 1.46, a current ratio of 3.44 and a debt-to-equity ratio of 1.15. Waters has a 52-week low of $167.93 and a 52-week high of $255.21. The company has a market cap of $15.06 billion, a price-to-earnings ratio of 25.24, a price-to-earnings-growth ratio of 2.29 and a beta of 1.08.

In other news, SVP Michael C. Harrington sold 22,400 shares of the company’s stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $234.93, for a total value of $5,262,432.00. Following the completion of the transaction, the senior vice president now directly owns 22,400 shares in the company, valued at $5,262,432. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Terrence P. Kelly sold 2,006 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $239.69, for a total transaction of $480,818.14. The disclosure for this sale can be found here. Insiders sold 30,130 shares of company stock valued at $7,119,281 over the last 90 days. Insiders own 1.14% of the company’s stock.

Several hedge funds have recently made changes to their positions in WAT. Fundsmith LLP raised its holdings in Waters by 0.9% in the first quarter. Fundsmith LLP now owns 5,026,757 shares of the medical instruments supplier’s stock valued at $1,265,285,000 after acquiring an additional 43,498 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Waters by 5.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,863,115 shares of the medical instruments supplier’s stock valued at $917,426,000 after acquiring an additional 267,576 shares in the last quarter. Geode Capital Management LLC raised its holdings in Waters by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 1,025,341 shares of the medical instruments supplier’s stock valued at $193,104,000 after acquiring an additional 50,700 shares in the last quarter. Northern Trust Corp raised its holdings in Waters by 5.9% in the first quarter. Northern Trust Corp now owns 991,892 shares of the medical instruments supplier’s stock valued at $249,670,000 after acquiring an additional 54,938 shares in the last quarter. Finally, Norges Bank acquired a new stake in Waters in the fourth quarter valued at $130,150,000. Institutional investors and hedge funds own 95.67% of the company’s stock.

About Waters

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Read More: Why do companies pay special dividends?

Get a free copy of the Zacks research report on Waters (WAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.